Author(s):
Vaibhav S. Gite, Rupali N. Nikam, Mukund M. Pache, Pragati B. Wankhede, Sagar S. Pawale, Avinash B. Darekar
Email(s):
mukundpache918@mail.com
DOI:
10.52711/2231-5691.2026.00044 
Address:
Vaibhav S. Gite1, Rupali N. Nikam1, Mukund M. Pache1, Pragati B. Wankhede1, Sagar S. Pawale1, Avinash B. Darekar2
1Department of Pharmacology, K.V.N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education & Research, Nashik, 422 002, Maharashtra, India.
2Principal, K. V. N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education & Research, Nashik, 422 002, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
Cancer remains a major global health challenge, causing nearly 10 million deaths annually. Advances in biomedical science have expanded treatment beyond conventional chemotherapy and radiotherapy to include targeted molecular agents, immunotherapies, and novel modalities. This review summarises cancer therapeutics across four domains: conventional, targeted, immunological, and emerging approaches. We examine the mechanisms, clinical efficacy, limitations, and innovations, outlining the evolution of oncological care and the integration of opportunities. Conventional modalities such as surgery, chemotherapy, and radiotherapy are discussed for their cytotoxic mechanisms and role in localised disease. Targeted therapies, including kinase inhibitors and monoclonal antibodies, are evaluated for molecular specificity and resistance. Immunological strategies, particularly immune checkpoint inhibitors and CAR-T cell therapy, are evaluated for their transformative impact. Emerging treatments, including oncolytic viruses, gene editing, and nanotechnology-based systems, are appraised for innovation and translational potential. While traditional methods retain relevance, combining them with precision medicine and immunological advances has yielded unprecedented efficacy in certain cancers. The future lies in personalised, synergistic regimens across these domains, supported by sustained interdisciplinary research and clinical validation.
Cite this article:
Vaibhav S. Gite, Rupali N. Nikam, Mukund M. Pache, Pragati B. Wankhede, Sagar S. Pawale, Avinash B. Darekar. Comprehensive Review of Conventional, Targeted, Immunological and Emerging Therapies in Cancer Treatment. Asian Journal of Pharmaceutical Research. 2026; 16(3):295-5. doi: 10.52711/2231-5691.2026.00044
Cite(Electronic):
Vaibhav S. Gite, Rupali N. Nikam, Mukund M. Pache, Pragati B. Wankhede, Sagar S. Pawale, Avinash B. Darekar. Comprehensive Review of Conventional, Targeted, Immunological and Emerging Therapies in Cancer Treatment. Asian Journal of Pharmaceutical Research. 2026; 16(3):295-5. doi: 10.52711/2231-5691.2026.00044 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2026-16-3-12
REFERENCES:
1. Cao W, Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal. 2021;134(7):783–791; doi: 10.1097/CM9.0000000000001474.
2. Vitale I, Shema E, Loi S, et al. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021; 27(2): 212–224; doi: 10.1038/s41591-021-01233-9.
3. Liu B, Zhou H, Tan L, et al. Exploring treatment options in cancer: tumor treatment strategies. Sig Transduct Target Ther 2024;9(1):175; doi: 10.1038/s41392-024-01856-7.
4. Debela DT, Muzazu SG, Heraro KD, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Medicine. 2021; 9:20503121211034366; doi: 10.1177/20503121211034366.
5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clinicians. 2021; 71(3): 209–249; doi: 10.3322/caac.21660.
6. Urla C, Fuchs J, Grimm A, et al. Interdisciplinary surgical approach enables complete tumor resection with preservation of neurological function in specific conditions of pediatric solid malignancies. J Cancer Res Clin Oncol. 2023; 149(8): 4497–4507; doi: 10.1007/s00432-022-04273-x.
7. Sorensen L, Lam AB, Moore VA, et al. Investigating perioperative interventions to enhance surgical outcomes for older adults with cancer: A systematic review. JCO. 2024; 42(16_suppl): e13765–e13765; doi: 10.1200/JCO.2024.42.16_suppl.e13765.
8. Burotto M, Wilkerson J, Stein WD, et al. Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Seminars in Oncology. 2019; 46(1): 83–99; doi: 10.1053/j.seminoncol.2019.01.002.
9. Ashley S, Choudhury A, Hoskin P, et al. Radiotherapy in metastatic bladder cancer. World J Urol. 2024; 42(1): 47; doi: 10.1007/s00345-023-04744-x.
10. Verginadis II, Citrin DE, Ky B, et al. Radiotherapy toxicities: mechanisms, management, and future directions. The Lancet. 2025; 405(10475): 338–352; doi: 10.1016/S0140-6736(24)02319-5.
11. Behranvand N, Nasri F, Zolfaghari Emameh R, et al. Chemotherapy: a double-edged sword in cancer treatment. Cancer Immunol Immunother. 2022; 71(3): 507–526; doi: 10.1007/s00262-021-03013-3.
12. Pache MM, Thorat AS, Mule RR, et al. Recent advances in the use of alkaloids as therapeutic agents: A pharmacognostic perspective. World Journal of Pharmaceutical Research. 2025; 14(2): 538–552.
13. López ÁG, Iarosz KC, Batista AM, et al. The role of dose density in combination cancer chemotherapy. Communications in Nonlinear Science and Numerical Simulation. 2019; 79: 104918; doi: 10.1016/j.cnsns.2019.104918.
14. Pache M, Nikam S. Antibiotic Resistance: Current Challenges and Future Directions. Int J of Pharm Sci. 2025; 3(1): 1600–1622; doi: 10.5281/ZENODO.14690670.
15. Qu Z. Investigating Conventional and Novel Methods for Treatment of Cancer. In: Proceedings of the 12th International Conference on Bioscience, Biochemistry and Bioinformatics ACM: Tokyo Japan; 2023; pp. 103–111; doi: 10.1145/3586139.3586154.
16. Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Sig Transduct Target Ther. 2020; 5(1): 22; doi: 10.1038/s41392-020-0116-z.
17. Huang XL, Khan MI, Wang J, et al. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis—New insight and futuristic vision. International Journal of Biological Macromolecules. 2021; 180: 739–752; doi: 10.1016/j.ijbiomac.2021.03.075.
18. Pottier C, Fresnais M, Gilon M, et al. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers. 2020; 12(3): 731; doi: 10.3390/cancers12030731.
19. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 2020; 86: 102017; doi: 10.1016/j.ctrv.2020.102017.
20. Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat. 2023; 197(1): 51–56; doi: 10.1007/s10549-022-06780-4.
21. Peterson C, Denlinger N, Yang Y. Recent Advances and Challenges in Cancer Immunotherapy. Cancers. 2022; 14(16): 3972; doi: 10.3390/cancers14163972.
22. Pache MM, Pangavhane RR. Immunotherapy in Autoimmune Diseases: Current Advances and Future Directions. Asian Journal of Pharmaceutical Research. 2025; 15(2): 183–191; doi: 10.52711/2231-5691.2025.00030.
23. Bod L, Kye Y-C, Shi J, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023; 619(7969): 348–356; doi: 10.1038/s41586-023-06231-0.
24. Zhou Y, Zhang Y, Guo G, et al. Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer. Clinical and Translational Med. 2020; 10(1): 107–115; doi: 10.1002/ctm2.14.
25. Chakrabarti R, Siegel D, Biran N. The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2025; 25(2): 96–108; doi: 10.1016/j.clml.2024.08.004.
26. Chohan KL, Siegler EL, Kenderian SS. CAR-T Cell Therapy: the Efficacy and Toxicity Balance. Curr Hematol Malig Rep 2023;18(2):9–18; doi: 10.1007/s11899-023-00687-7.
27. Fan T, Zhang M, Yang J, et al. Therapeutic cancer vaccines: advancements, challenges and prospects. Sig Transduct Target Ther. 2023; 8(1): 450; doi: 10.1038/s41392-023-01674-3.
28. Saxena M, Van Der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6): 360–378; doi: 10.1038/s41568-021-00346-0.
29. Zhang S, Zhao L, Guo M, et al. Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses. J Immunother Cancer. 2023; 11(7): e006785; doi: 10.1136/jitc-2023-006785.
30. Xue D, Hsu E, Fu Y-X, et al. Next-generation cytokines for cancer immunotherapy. Antibody Therapeutics 2021;4(2):123–133; doi: 10.1093/abt/tbab014.
31. Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023; 14: 1167975; doi: 10.3389/fimmu.2023.1167975.
32. Kewan T, Mirza S, Pine AB, et al. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood. 2023; 142(Supplement 1):2132–2132; doi: 10.1182/blood-2023-187295.
33. Pache M, Kedar H, Kond S, et al. Pharmacological Management of Neurodegenerative Disorders: Current and Future Approaches. Int J Sci R Tech. 2025; 2(3): 405–520; doi: 10.5281/ZENODO.15074000.
34. Li S, De Camargo Correia GS, Wang J, et al. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers. 2023; 15(11): 2899; doi: 10.3390/cancers15112899.
35. Ghule RJ, Jadhav PN, Sanap YN, Pache MM, Darekar AB. Tumour-derived extracellular vesicles in chemotherapy resistance: Molecular pathways, clinical implications and therapeutic opportunities. Asian J Res Pharm Sci. 2025; 15(4): 371–380. doi:10.52711/2231-5659.2025.00055
36. Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021; 374(6573): 1325–1326; doi: 10.1126/science.abk3436.
37. Shalhout SZ, Miller DM, Emerick KS, et al. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023; 20(3): 160–177; doi: 10.1038/s41571-022-00719-w.
38. Chen X-Z, Guo R, Zhao C, et al. A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. Front Pharmacol. 2022; 13: 939090; doi: 10.3389/fphar.2022.939090.
39. Pache MM, Pangavhane RR, Nikam SV, et al. CRISPR-Cas9 in Pharmaceutical Research: Applications, Challenges, Ethical Considerations and Future Directions. Asian Journal of Pharmacy and Technology. 2025.
40. Mueller KP, Piscopo NJ, Forsberg MH, et al. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression. J Immunother Cancer 2022;10(9):e004446; doi: 10.1136/jitc-2021-004446.
41. Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol. 2022; 13: 1029069; doi: 10.3389/fimmu.2022.1029069.
42. Rappaport AR, Kyi C, Lane M, et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2024; 30(4): 1013–1022; doi: 10.1038/s41591-024-02851-9.
43. Sun J, Yang Z, Teng L. Nanotechnology and Microtechnology in Drug Delivery Systems. Dose-Response 2020;18(2):155932582090781; doi: 10.1177/1559325820907810.
44. Hristova-Panusheva K, Xenodochidis C, Georgieva M, et al. Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology. Pharmaceuticals. 2024; 17(6): 677; doi: 10.3390/ph17060677.
45. Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Annals of Oncology. 2024; 35(1): 29–65; doi: 10.1016/j.annonc.2023.10.125.
46. Pache MM, Pangavhane RR, Jagtap MN, et al. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian J Res Pharm Sci. 2025; 15(1): 61–67; doi: 10.52711/2231-5659.2025.00009.
47. Bhinder B, Gilvary C, Madhukar NS, et al. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discovery. 2021; 11(4): 900–915; doi: 10.1158/2159-8290.CD-21-0090.
48. Anand U, Dey A, Chandel AKS, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2023; 10(4): 1367–1401; doi: 10.1016/j.gendis.2022.02.007.
49. Abraham I, Obeng-Kusi M, Roe D, et al. Comparative efficacy of later-line therapies for metastatic colorectal cancer (mCRC) using novel methods for patient survival data reconstruction and network meta-analysis (NMA) of survival curves. JCO. 2023; 41(16_suppl):e15611–e15611; doi: 10.1200/JCO.2023.41.16_suppl.e15611.
50. Min H-Y, Lee H-Y. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54(10): 1670–1694; doi: 10.1038/s12276-022-00864-3.
51. Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. The Lancet. 2021; 397(10278): 1010–1022; doi: 10.1016/S0140-6736(20)32598-8.
52. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA A Cancer J Clinicians. 2020; 70(2): 86–104; doi: 10.3322/caac.21596.
53. Shah RR, Curigliano G. Safety of Novel Targeted Therapies in Oncology. Drug Saf. 2019; 42(2): 157–158; doi: 10.1007/s40264-018-0770-z.
54. Nair NU, Greninger P, Zhang X, et al. A landscape of response to drug combinations in non-small cell lung cancer. Nat Commun. 2023; 14(1): 3830; doi: 10.1038/s41467-023-39528-9.
55. Tan AC, Bagley SJ, Wen PY, et al. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021; 9(7): e002459; doi: 10.1136/jitc-2021-002459.
56. Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment. CA A Cancer J Clinicians. 2018; 68(2): 153–165; doi: 10.3322/caac.21443.
57. Masina R, Caldas C. Precision Cancer Medicine 2.0—Oncology in the postgenomic era. Molecular Oncology. 2024; 1878–0261.13707; doi: 10.1002/1878-0261.13707.
58. Akhoundova D, Rubin MA. Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future. Cancer Cell. 2022; 40(9): 920–938; doi: 10.1016/j.ccell.2022.08.011.
59. Zheng J, Lu W, Wang C, et al. Unfolding the mysteries of heterogeneity from a high-resolution perspective: integration analysis of single-cell multi-omics and spatial omics revealed functionally heterogeneous cancer cells in ccRCC. Aging. 2024; 16(13): 10943–10971; doi: 10.18632/aging.205974.
60. Giordano C, Brennan M, Mohamed B, et al. Accessing Artificial Intelligence for Clinical Decision-Making. Front Digit Health. 2021; 3: 645232; doi: 10.3389/fdgth.2021.645232.
61. Madhavan S, Beckman RA, McCoy MD, et al. Envisioning the future of precision oncology trials. Nat Cancer. 2021; 2(1): 9–11; doi: 10.1038/s43018-020-00163-8.
62. El-Tanani M, Rabbani SA, Babiker R, et al. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Letters. 2024; 591: 216894; doi: 10.1016/j.canlet.2024.216894.
63. Su W, Qiu W, Li S, et al. A Dual‐Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis. Advanced Materials. 2023; 35(11): 2209379; doi: 10.1002/adma.202209379.
64. Sepich-Poore GD, Zitvogel L, Straussman R, et al. The microbiome and human cancer. Science. 2021; 371(6536): eabc4552; doi: 10.1126/science.abc4552.
65. Berger ML, Ganz PA, Zou KH, et al. When Will Real-World Data Fulfill Its Promise to Provide Timely Insights in Oncology? JCO Clin Cancer Inform. 2024; 8: e2400039; doi: 10.1200/CCI.24.00039.
66. Anonymous. Innovations in Cancer Research and Treatment. Au Herb Insight. 2024; 7(1): 1–12; doi: 10.25163/ahi.7120050.